David A Zopf

USPTO Granted Patents = 44 (Patent Applications = 11)

CIPO Patents = 5 (Patent Applications = 3)

EPO Patents = 18 (Patent Applications = 14)

Average Co-Inventor Count = 4.6

ph-index = 25

Forward Citations = 1,363(Granted Patents)

Location History:

Strafford, PA (US) (1996 - 2004)
Wayne, PA (US) (2006 - 2015)

Company Filing History:

24 out of 50

Neose Technologies, Inc.

Neose Pharmaceuticals, Inc.

Years Active: 1996-2015

Loading Chart...

44 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9050304 - Methods of treatment using glycopegylated G-CSF (2015-06-09),

2. 9029331 - Glycopegylated granulocyte colony stimulating factor (2015-05-12),

3. 8916360 - Glycopegylated erythropoietin (2014-12-23),

4. 8911967 - One pot desialylation and glycopegylation of therapeutic peptides (2014-12-16),

5. 8853161 - Glycopegylation methods and proteins/peptides produced by the methods (2014-10-07),

6. 8716240 - Erythropoietin: remodeling and glycoconjugation of erythropoietin (2014-05-06),

7. 8716239 - Granulocyte colony stimulating factor: remodeling and glycoconjugation G-CSF (2014-05-06),

8. 8633157 - Glycopegylated erythropoietin (2014-01-21),

9. 8361961 - O-linked glycosylation of peptides (2013-01-29),

10. 8268967 - Glycopegylated interferon α (2012-09-18),

11. 8076292 - Factor VIII: remodeling and glycoconjugation of factor VIII (2011-12-13),

12. 8063015 - Glycopegylation methods and proteins/peptides produced by the methods (2011-11-22),

13. 8008252 - Factor VII: remodeling and glycoconjugation of Factor VII (2011-08-30),

14. 7956032 - Glycopegylated granulocyte colony stimulating factor (2011-06-07),

15. 7842661 - Glycopegylated erythropoietin formulations (2010-11-30),

Title: **David A. Zopf: Innovator in Glycopegylated Therapeutics**

Introduction

David A. Zopf, based in Wayne, Pennsylvania, is a prolific inventor with an impressive portfolio of 44 patents. His work primarily focuses on advancements in therapeutic treatments, particularly related to hematopoiesis and glycopegylated proteins. Zopf's latest contributions have targeted improving the efficacy of treatments in subjects undergoing radiation or chemotherapy.

Latest Patents

Among his latest patents is "Methods of treatment using glycopegylated G-CSF," which presents a glycopegylated form of Granulocyte Colony Stimulating Factor (G-CSF) that exhibits enhanced pharmacokinetic properties compared to its conventional counterparts. This innovative treatment aims to mobilize hematopoiesis in patients, specifically those affected by the myelosuppressive effects of cytotoxic therapies.

Another significant patent is for "Glycopegylated granulocyte colony stimulating factor," detailing methods for preparing and purifying G-CSF conjugates linked to PEG moieties. This patent emphasizes the use of various chromatography techniques for the purification of these conjugates, further enhancing their therapeutic potential.

Career Highlights

David has contributed his expertise to notable companies in the biopharmaceutical sector, including Neose Technologies, Inc. and Novo Nordisk A/S. His work in these organizations has been instrumental in advancing therapeutic innovations that aim to improve patient care and outcomes.

Collaborations

Throughout his career, Zopf has collaborated with talented professionals, including Shawn DeFrees and Caryn Bowe. Together, they have worked on developing cutting-edge solutions within the realm of biotechnology and pharmaceuticals.

Conclusion

David A. Zopf's dedication to innovation in therapeutic treatments is evident in his extensive patent portfolio and collaborative efforts. His focus on glycopegylated therapeutics showcases his commitment to improving the lives of patients undergoing challenging medical treatments, ensuring that advancements in medical science continue to evolve.

This text is generated by artificial intelligence and may not be accurate.